# Bioequivalence Study of Tamsulosin 0.4 mg Sustained Release Film-coated Tablets

> **NCT06558032** · PHASE1 · COMPLETED · sponsor: **Dexa Medica Group** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia)
- **DRUG:** Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)

## Key facts

- **NCT ID:** NCT06558032
- **Lead sponsor:** Dexa Medica Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-06
- **Primary completion:** 2023-12-16
- **Final completion:** 2024-02-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06558032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06558032, "Bioequivalence Study of Tamsulosin 0.4 mg Sustained Release Film-coated Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06558032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*